Press Release: Francis Medical Announces Close of $55 Million Series B Equity Financing

2021-09-15T02:31:36-05:00September 15th, 2021|In the Press|

September 15, 2021: Francis Medical today announced the completion of the company’s $55.0 million Series B equity financing. The company plans to use the Series B proceeds to fund the development of its proprietary prostate cancer treatment through FDA 510(k) approval, which includes a pivotal clinical study (VAPOR 2) for the management of prostate cancer, scheduled to begin enrollment in August 2022.